I5B-MC-JGDQ - ClinicalTrials.gov - NCT03126591
I5B-MC-JGDQ - ClinicalTrials.gov - NCT03126591
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology
Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)
Participant must have an anticipated life expectancy of 3 months or more
Participants must NOT
Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years
Participant must not have received a live-virus vaccine within 30 days of planned treatment
Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years
Trial Summary
Conditions the trial is for
Soft Tissue Sarcoma
What the trial is testing?
Olaratumab, Pembrolizumab
Could I receive a Placebo?
no
Enrollment Goal
37
Trial Dates
July 2017 - March 2021
Trial Phase
1
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology
Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)
Participant must have an anticipated life expectancy of 3 months or more
Participants must NOT
Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years
Participant must not have received a live-virus vaccine within 30 days of planned treatment
Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years
Trial Summary
Conditions the trial is for
Soft Tissue Sarcoma
What the trial is testing?
Olaratumab, Pembrolizumab
Could I receive a Placebo?
no
Enrollment Goal
37
Trial Dates
July 2017 - March 2021
Trial Phase
1
Trial Locations
Hide locations not currently recruiting